Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

RAB0637

Sigma-Aldrich

Human CD80 / T-lymphocyte Activation Antigen CD80 ELISA Kit

Sign Into View Organizational & Contract Pricing

Select a Size

96 WELLS
$655.00

$655.00

Usually Ships in 4 Weeks. (Orders outside of US, please allow an additional 1-2 weeks for delivery)
All Photos(1)

Select a Size

Change View
96 WELLS
$655.00

About This Item

UNSPSC Code:
41116158
NACRES:
NA.84

$655.00

Usually Ships in 4 Weeks. (Orders outside of US, please allow an additional 1-2 weeks for delivery)

species reactivity

human

packaging

kit of 96 wells (12 strips x 8 wells)

technique(s)

ELISA: suitable

input

sample type serum
sample type cell culture supernatant(s)
sample type plasma

assay range

inter-assay cv: <12%
intra-assay cv: <10%
sensitivity: 12 pg/mL
standard curve range: 12.29-3000 pg/mL

detection method

colorimetric

shipped in

wet ice

storage temp.

−20°C

Gene Information

human ... CD80(941)

General description

The antibody pair provided in this kit recognizes human B7-1 / CD80.

Application

For research use only. Not for use in diagnostic procedures.
Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)

Kit Components Also Available Separately

Product No.
Description
SDS
  • RABTMB3ELISA Colorimetric TMB Reagent (HRP Substrate, Item H)SDS
  • RABSTOP3ELISA Stop Solution (Item I)SDS
  • RABWASH420X Wash Buffer (Item B)SDS

pictograms

Corrosion
GHS05

signalword

Warning

hcodes

H290

Hazard Classifications

Met. Corr. 1

Storage Class

8A - Combustible corrosive hazardous materials

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
SAMPLE

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jingbo Zhai et al.
International immunopharmacology, 59, 1-11 (2018-04-01)
Low immunogenicity is one of the major problems limiting the clinical use for DNA vaccines, which makes it impossible to obtain a strong protective immune response after vaccination. In order to explore whether Ag85A DNA vaccine could mount more efficiently
Anatilde M Gonzalez Guerrico et al.
Kidney international reports, 5(11), 2021-2031 (2020-11-10)
Heterogeneity of nephrotic diseases and a lack of validated biomarkers limits interventions and reduces the ability to examine outcomes. Urinary CD80 is a potential biomarker for minimal change disease (MCD) steroid-sensitive nephrotic syndrome (NS). We investigated and validated a CD80
Amy Haseley Thorne et al.
Frontiers in immunology, 11, 327-327 (2020-03-13)
Overcoming tolerance to tumor-associated antigens remains a hurdle for cancer vaccine-based immunotherapy. A strategy to enhance the anti-tumor immune response is the inclusion of adjuvants to cancer vaccine protocols. In this report, we generated and systematically screened over twenty gene-based
Vijith Vijayan et al.
Redox biology, 22, 101147-101147 (2019-03-03)
Macrophages adopt different phenotypes in response to microenvironmental changes, which can be principally classified into inflammatory and anti-inflammatory states. Inflammatory activation of macrophages has been linked with metabolic reprogramming from oxidative phosphorylation to aerobic glycolysis. In contrast to mouse macrophages

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service